TW201819919A - 於利用pd-1訊息抑制劑之疾病治療中之有效性判定標記 - Google Patents
於利用pd-1訊息抑制劑之疾病治療中之有效性判定標記 Download PDFInfo
- Publication number
- TW201819919A TW201819919A TW106137915A TW106137915A TW201819919A TW 201819919 A TW201819919 A TW 201819919A TW 106137915 A TW106137915 A TW 106137915A TW 106137915 A TW106137915 A TW 106137915A TW 201819919 A TW201819919 A TW 201819919A
- Authority
- TW
- Taiwan
- Prior art keywords
- cells
- treatment
- metabolites
- subject
- message
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/008—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions for determining co-enzymes or co-factors, e.g. NAD, ATP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Ecology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016214785 | 2016-11-02 | ||
JP2016-214785 | 2016-11-02 | ||
JP2017151547 | 2017-08-04 | ||
JP2017-151547 | 2017-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201819919A true TW201819919A (zh) | 2018-06-01 |
Family
ID=62076785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106137915A TW201819919A (zh) | 2016-11-02 | 2017-11-02 | 於利用pd-1訊息抑制劑之疾病治療中之有效性判定標記 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11662339B1 (ja) |
EP (1) | EP3536802B1 (ja) |
JP (1) | JP7374415B2 (ja) |
CN (1) | CN109996886A (ja) |
TW (1) | TW201819919A (ja) |
WO (1) | WO2018084204A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018180007A1 (ja) * | 2017-03-31 | 2018-10-04 | ソニー株式会社 | 情報処理装置、情報処理方法、及び細胞分析システム |
JPWO2019187673A1 (ja) * | 2018-03-29 | 2021-04-08 | ソニー株式会社 | 情報処理装置、情報処理方法及びプログラム |
WO2020123806A1 (en) * | 2018-12-14 | 2020-06-18 | Beth Israel Deaconess Medical Center. Inc. | Modulation of pd-1 |
CN113226370A (zh) * | 2019-01-04 | 2021-08-06 | 国立大学法人京都大学 | 利用含有pd-1信号抑制剂的药剂的治疗有效性的预测和/或判定标记 |
WO2020168541A1 (zh) * | 2019-02-22 | 2020-08-27 | 深圳华大生命科学研究院 | 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途 |
CN111537594B (zh) * | 2020-05-12 | 2023-03-28 | 南通大学 | 李斯特菌在筛选细胞呼吸链抑制药物上的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2478400C2 (ru) * | 2006-12-27 | 2013-04-10 | Эмори Юниверсити | Композиции и способы лечения инфекций и опухолей |
KR20160070154A (ko) * | 2013-11-06 | 2016-06-17 | 랩터 파마슈티컬스 인코포레이티드 | 미토콘드리아병을 치료하기 위한 시스테아민 및 이의 유도체의 용도 |
CA2954446A1 (en) * | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
GB201413162D0 (en) | 2014-07-24 | 2014-09-10 | Immusmol Sas | Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway |
JP2016064989A (ja) * | 2014-09-22 | 2016-04-28 | 国立研究開発法人国立がん研究センター | 癌を治療するための医薬組成物、およびpd−1阻害剤による治療に対する感受性を評価する方法 |
JP6087983B2 (ja) | 2015-05-26 | 2017-03-01 | 合資会社三和歯ブラシ工業所 | 舌ブラシの製造方法 |
JP2017151547A (ja) | 2016-02-22 | 2017-08-31 | 株式会社デンソー | 運転支援制御報知システムおよび報知装置 |
-
2017
- 2017-11-01 US US16/346,566 patent/US11662339B1/en active Active
- 2017-11-01 EP EP17867434.7A patent/EP3536802B1/en active Active
- 2017-11-01 WO PCT/JP2017/039619 patent/WO2018084204A1/ja unknown
- 2017-11-01 CN CN201780066425.4A patent/CN109996886A/zh active Pending
- 2017-11-01 JP JP2018549058A patent/JP7374415B2/ja active Active
- 2017-11-02 TW TW106137915A patent/TW201819919A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP7374415B2 (ja) | 2023-11-09 |
WO2018084204A1 (ja) | 2018-05-11 |
EP3536802A1 (en) | 2019-09-11 |
EP3536802B1 (en) | 2021-10-13 |
US11662339B1 (en) | 2023-05-30 |
CN109996886A (zh) | 2019-07-09 |
EP3536802A4 (en) | 2020-07-29 |
JPWO2018084204A1 (ja) | 2019-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201819919A (zh) | 於利用pd-1訊息抑制劑之疾病治療中之有效性判定標記 | |
JP7073254B2 (ja) | 癌における「免疫チェックポイント介入」 | |
Hollmann et al. | Inhibition of acid sphingomyelinase allows for selective targeting of CD4+ conventional versus Foxp3+ regulatory T cells | |
TW202043773A (zh) | 藉由含有pd-1訊息抑制劑之藥劑之治療有效性之預測及/或判定標記 | |
Yang et al. | Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy | |
JP2016515383A (ja) | 樹状細胞応答遺伝子発現、組成物およびその使用方法 | |
De Biasi et al. | Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients | |
Yang et al. | Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy | |
Bhatta et al. | Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments | |
Packiriswamy et al. | Oxidative stress-induced mitochondrial dysfunction in a normal colon epithelial cell line | |
Bozorgmehr et al. | CD71+ erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors | |
Xiao et al. | HRS Regulates Small Extracellular Vesicle PD-L1 Secretion and Is Associated with Anti–PD-1 Treatment Efficacy | |
De Ponte Conti et al. | mTOR-dependent translation drives tumor infiltrating CD8+ effector and CD4+ Treg cells expansion | |
WO2021030679A2 (en) | Compositions and methods for diagnosis and treatment of metabolic diseases and disorders | |
Levine et al. | Single-cell metabolic analysis by mass cytometry reveals distinct transitional states of CD8 T cell differentiation | |
CN105142662A (zh) | Idh1 r132h突变阳性癌症治疗或诊断的手段与方法 | |
Jay et al. | Bim mediates the elimination of functionally unfit Th1 responders from the memory pool | |
Levine et al. | Single-cell metabolic dynamics of early activated CD8 T cells during the primary immune response to infection | |
Gattlen et al. | Use of a novel microbiome modulator improves anticancer immunity in a murine model of malignant pleural mesothelioma | |
Taranta et al. | Magnetically driven bioreactors as new tools in drug delivery | |
Humeau et al. | Immunogenic Cell Death in Cancer | |
Min | Art of tumor immunity: extricating hypoxia-driven immunosuppression in the solid tumor microenvironment | |
EP3422003A1 (en) | Method for determining if a patient is at risk of having or developing a colorectal cancer (crc) | |
Shao et al. | Intrinsic unresponsiveness of Mertk−/− B cells to chronic graft-versus-host disease is associated with unmodulated CD1d expression | |
Dertli et al. | Are Pattern Recognition Receptors Associated with Hepatocellular Carcinoma? |